ERBB2 and breast cancer: Multivariate logistic regression models were used to identify independent predictors of trastuzumab resistance, and ROC curves analysis was conducted to evaluate the predictive value of ALBI score and patients age.<h4>Results</h4>This study included 95 female patients with HER-2 positive BC treated with trastuzumab, aged 31-71 years (mean age 53.15 ± 10.063 years).